Group
Companies
History
Business model
Mission and vision
Corporate values
Commitment to sport
Research
Pharmaceutical Research
Sucrosomial Technology
Cetylated Fatty Acids
Quality and certifications
Brands
PharmaNutra
Junia Pharma
Alesco
Akern
Investor
INVESTOR RELATIONS
Stock performance
Share capital and Shareholders
Shares study and research
Broker
Financial statements
Presentations
Corporate events
Company presentation
Notice of meetings
SDIR
AIM admission document
MTA prospectus
PRESS
Press releases
Press review
Governance
Code of Ethics
231 Model
Board of Directors and Committees
Company documents
Internal dealing
Shareholders’ meeting
Statutory auditors and Audit firm
Sharholders Agreements
Sustainability
News
Science
Corporate
Events
Social commitment
Careers
Work with us
Job offers
Job application
Group
Companies
History
Business model
Mission and vision
Corporate values
Commitment to sport
Research
Pharmaceutical Research
Sucrosomial Technology
Cetylated Fatty Acids
Quality and certifications
Brands
PharmaNutra
Junia Pharma
Alesco
Akern
Investor
INVESTOR RELATIONS
Stock performance
Share capital and Shareholders
Shares study and research
Broker
Financial statements
Presentations
Corporate events
Company presentation
Notice of meetings
SDIR
AIM admission document
MTA prospectus
PRESS
Press releases
Press review
Governance
Code of Ethics
231 Model
Board of Directors and Committees
Company documents
Internal dealing
Shareholders’ meeting
Statutory auditors and Audit firm
Sharholders Agreements
Sustainability
News
Science
Corporate
Events
Social commitment
Careers
Work with us
Job offers
Job application
it
en
08 November 2023
MODEL DISCLOSURE FOR TRANSACTIONS IN THE ISSUER’S SECURITIES
06 November 2023
BOD APPROVES INTERIM MANAGEMENT REPORT AS AT 30/09/2023
10 October 2023
PHARMANUTRA S.P.A.: INITIATION OF SHARE BUY-BACK PROGRAM
03 October 2023
PHARMANUTRA S.P.A.: FIRST SALES ON THE US MARKET
19 September 2023
PHARMANUTRA S.P.A.: HALF-YEAR FINANCIAL REPORT AS OF 30 JUNE 2023
12 September 2023
POLICY FOR THE MANAGEMENT OF THE DIALOGUE WITH ALL SHAREHOLDERS OF PHARMANUTRA S.P.A.
11 September 2023
PHARMANUTRA S.P.A.: THE BOD APPROVED THE FIRST HALF FINANCIAL REPORT AS AT 30 JUNE 2023
30 August 2023
PHARMANUTRA S.P.A.: LIPOCET (CETILAR®) GETS THE GREEN LIGHT TO BE CLASSIFIED AS A ‘NOVEL FOOD’ ALSO IN THE UK
03 August 2023
PHARMANUTRA S.P.A.: CETILAR® WITH MARCELL JACOBS HEADING FOR PARIS 2024
17 July 2023
PHARMANUTRA S.P.A.: THE BOARD OF DIRECTORS APPROVES THE 2022 SUSTAINABILITY REPORT AND APPOINTS THE SUSTAINABILITY GOVERNANCE
11 July 2023
PHARMANUTRA S.P.A.: CETILAR® IS RECONFIRMED AS MAIN SPONSOR OF THE PISA SPORTING CLUB FOR 2023-2024
26 May 2023
PHARMANUTRA S.P.A.: CETILAR® SIDE BY SIDE WITH FERNANDO ALONSO
1
2
…
17
>